Stronger Together
A toolkit and information resource by patients for patients to help those living with Inflammatory Bowel Disease.
This helpful resource is brought to you by the Patient Advisory Council of ImproveCareNow.
Get the information you need.
Get the information you need.
Your personal resources here.
More resources for you
Toolkits
Materials on this webpage are created by members of the ImproveCareNow Community. Do not rely on the information in these documents or resources to diagnose or treat any health condition. This information does not constitute medical advice and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. All disclaimers found on this page apply to documents on this webpage.
Supporting Each Other
Living with Inflammatory Bowel Disease is hard enough. Doing it alone is even harder. The Patient Advisory Council in partnership with ImproveCareNow has created this resource for young people to be educated and empowered. By sharing ideas, tips, and resources, we become a force of knowledge against IBD. As a voice for IBD patients, PAC members contribute to research studies to improve health care innovations and develop better treatments for all of us.
Let’s rely on each other because we’re stronger together.
Featured Posts
Why was this study done?
Pediatric patients with inflammatory bowel disease (IBD), including Crohn’s Disease and ulcerative colitis, who take biologic medications (like infliximab and adalimumab) have decreased hospitalizations, surgery rates, and improved quality of life. However, biologic medicines are expensive. Biosimilars are similar biological therapies that are just as safe and effective as the original biologic medication, although they are often less expensive. There are currently two medications (infliximab/Remicade and adalimumab/Humira) used to treat IBD that have biosimilars available. Despite the cost savings, the utilization of biosimilars in the treatment of IBD has been low. The exact reasons why the utilization of biosimilars is low is not well known or well-studied.
The objective of this study was to evaluate pediatric gastroenterologists’ perspectives of biosimilars and to evaluate factors that impact pediatric gastroenterologists’ comfort level with prescribing biosimilars.
This spring, Teresa (a self-proclaimed dataphile) led a breakout session at our Live Online Community Conference where she and Dr. Howard Baron (ICN physician leader) talked openly about data entry failure at their center with the hope that others could learn from their experience.
POV: You can love data and still fail data entry
Sep 06, 2023
Hi, my name is Justin, and I was diagnosed with Crohn's disease in 2021. I am on Remicade. I am currently a rising junior in high school, and my interests are in law.
I struggle with what I eat on a...
Aug 02, 2023
My name is Maria and I'm the ImproveCareNow Parent/Family Advisory Council (PFAC) Connections Co-Lead. Recently, I had the pleasure of collaborating with the ICN Communications team and PFAC leadership, to create the very first logo for the PFAC! Our new PFAC logo symbolizes the incredible strength and unwavering unity of parents and caregivers who nurture and support children with IBD.
The story of our new PFAC logo
Jul 18, 2023
Join the PAC
Together, we can make a difference. Join the Patient Advisory Council today and be the voice for others with IBD.
Sign up